MARCOS YASSA: Open Payments
NPI 1952899742 · NEW BALTIMORE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,228 in 47 payments from 11 companies in 2025. Trend: 2023 $1,381 · 2024 $1,452 · 2025 $1,228
Food & beverage: $1,228
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $250 |
| Alkermes, Inc. | 10 | $243 |
| Otsuka America Pharmaceutical, Inc. | 5 | $206 |
| ABBVIE INC. | 12 | $148 |
| Indivior Inc. | 6 | $132 |
| Braeburn Inc. | 3 | $73 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
Products named: ARISTADA, REXULTI, VRAYLAR, SUBLOCADE, AUSTEDO XR, UZEDY, BRIXADI, Auvelity.
Industry payments across MI — which companies pay providers there.
